We serve Chemical Name:methyl (2S)-4-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate CAS:120042-11-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![methyl (2S)-4-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate](https://a.dearchem.com/CAS2/120042-11-7.png)
Chemical Name:methyl (2S)-4-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate
CAS.NO:120042-11-7
Synonyms:L-Homoserine, N-[(1,1-dimethylethoxy)carbonyl]-, methyl ester;N-BOC-L-HOMOSERINE METHYL ESTER;N-tert-Butoxycarbonyl-L-homoserine Methyl Ester;Methyl N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-homoserinate;Boc-L-homoserine methyl ester
Molecular Formula:C10H19NO5
Molecular Weight:233.262
HS Code:2924199090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:364.6±37.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.462
PSA:88.35000
Exact Mass:233.126328
LogP:1.29
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like L-Homoserine, N-[(1,1-dimethylethoxy)carbonyl]-, methyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Boc-L-homoserine methyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-BOC-L-HOMOSERINE METHYL ESTER Use and application,Methyl N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-homoserinate technical grade,usp/ep/jp grade.
Related News: Our COVID-19 vaccine, Vaxzevria, undergoes extremely robust safety and quality testing prior to becoming available for patients. oxan-4-yl carbonochloridate manufacturers After examining all the evidence, it was clear that more plausible explanations for the AML cases included the conditioning treatment the patients received to clear out bone marrow cells and the higher risk of blood cancer in people with sickle cell disease. Perovskite FAPbCl3 Powder suppliers A new post-hoc analysis of pooled data from the TULIP phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures each, compared to placebo, in patients with moderate to severe systemic lupus erythematosus (SLE). Ethyl 3-hydroxy-1H-indole-2-carboxylate vendor & factory.
